Therapeutic effects of quetiapine on memory deficit and brain β-amyloid plaque pathology in a transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 3, 2013, Pages 270-278

  Zhu, Shenghua ^a   He, Jue ^a   Zhang, Ruiguo ^a,b   Kong, Lynda ^a   Tempier, Adrien ^a   Kong, Jiming ^c   Li, Xin Min ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NONE

Author keywords

amyloid; Alzheimer's disease; APP PS1 double transgenic mouse model; Memory; Plaque; Quetiapine

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PRESENILIN 1; QUETIAPINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; ANIMALS; BLOTTING, WESTERN; BRAIN; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PLAQUE, AMYLOID;

EID: 84876846625     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310030006     Document Type: Article

References (83)

1. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 25(2): 81-97 (1999).
2. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science: 298(5594): 789-791 (2002).
3. Van Gassen G, Annaert W. Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 9(2): 117-126 (2003).
4. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54(3): 469-525 (2002).
5. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164(2): 719-725 (2004).
6. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120(5): 701-713 (2005).
7. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20(4): 154-159 (1997).
8. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature: 373(6514): 523-527 (1995).
9. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-102 (1996).
10. Sturchler-Pierrat C, Abramowski D, Duke M, Duke M, Wiederhold KH, Mistl C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94(24): 13287-13292 (1997).
11. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4(1): 97-100 (1998).
12. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 30(8): 1205-1216 (2009).
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356 (2002).
14. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4): 545-555 (2005).
15. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8(8): 1051-1058 (2005).
16. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27(4): 796-807 (2007).
17. Purdon SE, Malla A, Labelle A, and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26(2): 137-149 (2001).
18. Jeste DV, Dolder CR. Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res 38(1): 73-103 (2004).
19. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 19(1): 29-35 (2004).
20. Madhusoodanan S, Shah P, Brenner R, and Gupta S. Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? CNS Drugs 21(2): 101-115 (2007).
21. He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res 172(1): 39-45 (2006).
22. He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav. Brain Res 160(1): 178-187 (2005).
23. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168(2): 236-242 (2006).
24. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29(8): 1426-1431 (2004).
25. Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM, et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 39(3): 353-360 (2007).
26. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry 57(5): 533-542 (2005).
27. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol. Life Sci 64(15): 1930-1944 (2007).
28. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205(12): 2781-2789 (2008).
29. Leroy K, Yilmaz Z, and Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol 33(1): 43-55 (2007).
30. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602): 710-713 (1996).
31. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 13(7): 697-708 (2008).
32. Yamada K, Noda Y, Hasegawa T, Komori Y, Nikai T, Sugihara H, et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther 276(2): 460-466 (1996).
33. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci. Methods 11(1): 47-60 (1984).
34. Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp (21) (2008).
35. Liu L, Herukka SK, Minkeviciene R, van Groen T, Tanila H. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis 17(3): 516-523 (2004).
36. Meyding-Lamade U, Krieger D, Schnabel P, Sartor K, Sack FU, Gass P, et al. Cerebral metastases of an allogenic renal cell carcinoma in a heart recipient without renal cell carcinoma. J Neurol 243(5): 425-427 (1996).
37. Franklin KBJ, Paxinos G, The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press (1997).
38. Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Y, et al. Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 19(12): 1247-1253 (2009).
39. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, et al. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. The Journal of neuroscience: the official journal of the Society for Neuroscience 28(45): 11622-11634 (2008).
40. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloidbeta precursor protein processing. Biochemistry 43(22): 6899-6908 (2004).
41. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29(2): 95-102 (2004).
42. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24(4): 627-633 (2006).
43. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891(1-2): 42-53 (2001).
44. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J Pathol 158(4): 1345-1354 (2001).
45. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22(3): 377-385 (2001).
46. Puolivali J, Wang J, Heikkinen T, Heikkilä M, Tapiola T, van Groen T, et al. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 9(3): 339-347 (2002).
47. Schmitz C, Rutten BP, Pielen A, Schäfer S, Wirths O, Tremp G, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J Pathol 164(4): 1495-1502 (2004).
48. McDonald RJ, Craig LA, and Hong NS. The etiology of agerelated dementia is more complicated than we think. Behav. Brain Res 214(1): 3-11 (2010).
49. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28(16): 4231-4237 (2008).
50. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842 (2008).
51. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4): 572-580 (1991).
52. Masliah E, Miller A, Terry RD. The synaptic organization of the neocortex in Alzheimer's disease. Med Hypotheses 41(4): 334-340 (1993).
53. Allison DW, Chervin AS, Gelfand VI, Craig AM. Postsynaptic scaffolds of excitatory and inhibitory synapses in hippocampal neurons: maintenance of core components independent of actin filaments and microtubules. J Neurosci 20(12): 4545-4554 (2000).
54. Aoki C, Sekino Y, Hanamura K, Fujisawa S, Mahadomrongkul V, Ren Y, et al. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J Comp. Neurol 483(4): 383-402 (2005).
55. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 324(3): 209-212 (2002).
56. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43(5): 633-645 (2004).
57. Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, Steinbusch HW, et al. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol 167(1): 161-173 (2005).
58. Standridge JB. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Curr. Alzheimer Res 3(2): 95-108 (2006).
59. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100(18): 10417-10422 (2003).
60. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102(7): 2273-2276 (2005).
61. Zeng Y, Zhao D, Xie CW. Neurotrophins enhance CaMKII activity and rescue amyloid-beta-induced deficits in hippocampal synaptic plasticity. J Alzheimers Dis 21(3): 823-831 (2010).
62. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 321(1-2): 65-68 (2002).
63. Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 15(13): 2109-2112 (2004).
64. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 1010(1-2): 81-86 (2004).
65. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281(5381): 1322-1326 (1998).
66. Bruckheimer EM, Cho SH, Sarkiss M, Herrmann J, McDonnell TJ. The Bcl-2 gene family and apoptosis. Adv Biochem En. Biotechnol 62: 75-105 (1998).
67. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 81(4): 572-580 (2005).
68. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to longterm potentiation. Eur J Neurosci 25(1): 81-86 (2007).
69. Zhu LQ, Liu D, Hu J, Cheng J, Wang SH, Wang Q, et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 30(10): 3624-3633 (2010).
70. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27(45): 12211-12220 (2007).
71. Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15(2): 181-191 (2008).
72. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 67(2): 699-707 (1996).
73. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J: 359(Pt 1): 1-16 (2001).
74. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163(1): 83-95 (2003).
75. Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther 28(10): 1695-1700 (2006).
76. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 16(2): 128-130 (2002).
77. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355(15): 1525-1538 (2006).
78. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 168(8): 831-839 (2011).
79. Garcia-Alberca JM, Pablo Lara J, Gonzalez-Baron S, Barbancho MA, Porta D, Berthier M. Prevalence and comorbidity of neuropsychiatric symptoms in Alzheimer's disease. Actas Esp Psiquiatr 36(5): 265-270 (2008).
80. Wang H, He J, Zhang R, Zhu S, Wang J, Kong L, et al. Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease. Behav Brain Res 233(1): 237-243 (2012).
81. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156(2): 286-293 (1999).
82. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156(6): 876-884(1999).
83. He J, Kong J, Tan QR, Li XM. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adh Migr 3(1): 129-137 (2009).